Phase 2
N=35
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
Schizophrenia
Bottom Line
View on ClinicalTrials.gov: NCT05623228 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal Test — 12.09; 19.04; 7.71; 14.00 score on a scale — p=.00
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia (Combination_product)
- Age
- Adult · 19+ yrs
- Sex
- All
- Sponsor
- Rakitzi, Stavroula
- Primary completion
- Mar 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal Test |
12.09; 19.04; 7.71; 14.00 | .00 sig |
| PRIMARY Symptoms, PANSS Greek Version |
113.62; 70.18 | .04 sig |
| PRIMARY Functional Outcome |
33.47; 30.49 | .00 sig |
| PRIMARY Recovery |
90.62; 125.56 | .04 sig |
| SECONDARY Intelligent Quotient |
86.17 | .00 sig |
Summary
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia.
Is it effective and efficacious?
Eligibility Criteria
Inclusion Criteria
- Diagnosis of schizophrenia
- No relapse and hospitalization
- Ambulant psychiatric treatment
Exclusion Criteria
- Other psychotic disorders
- Relapse and hospitalization
- Substance abuse
Data sourced from ClinicalTrials.gov (NCT05623228). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.